INmune Bio Advances XPro Toward Registrational Alzheimer’s Study

Inmune Bio ( (INMB) ) has shared an announcement.

INmune Bio Inc., a clinical-stage biotechnology company specializing in inflammation and immunology, is advancing a pipeline that includes CORDStrom™ for rare dermatologic disease, XPro™ as a selective soluble TNF inhibitor targeting neuroinflammation in Alzheimer’s disease, and INKmune® for oncology. The Nasdaq-listed company focuses on targeting the innate immune system to develop novel therapies for neurologic and cancer indications.

On February 22, 2026, INmune Bio announced it will host a webinar on February 27, 2026, to outline the registrational pathway for its Alzheimer’s candidate XPro1595 following completion of the Phase 2 MINDFuL trial and an End-of-Phase 2 meeting with the FDA. Management says the agency’s feedback supports advancing XPro™ into a registrational study in Alzheimer’s patients with inflammatory biomarkers, and the event will detail Phase 2 data, proposed Phase 3-ready study design, and the company’s strategy to pursue a global partnership to maximize the drug’s clinical and commercial potential.

The webinar will feature key opinion leaders and MINDFuL trial investigators Dr. Michael Woodward of Austin Health in Melbourne and Dr. Sharon Cohen of the Toronto Memory Program, who will present trial findings and discuss implications for treating early Alzheimer’s disease with inflammation. Their participation underscores INmune Bio’s effort to strengthen its scientific credibility and engage the neurology community as it prepares to move XPro™ into late-stage development.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Score is held back primarily by weak financial performance (large losses and sustained cash burn). The latest earnings call provides a meaningful offset via improved quarterly loss profile, stated cash runway into late 2026, and defined regulatory milestones, while technicals are mixed and valuation is constrained by negative earnings and no dividend.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Its product platforms include CORDStrom™ for conditions such as recessive dystrophic epidermolysis bullosa, XPro™ for inflammation-driven neurologic disorders like Alzheimer’s disease, and INKmune® for priming natural killer cells in cancer.

The company concentrates on next-generation immunotherapies that modulate tumor necrosis factor and harness cell-based approaches to address unmet medical needs. With a late-stage pipeline and emphasis on inflammation and immunology, INmune Bio is positioning its assets for potential global partnerships and future registrational studies in neurology and oncology.

Average Trading Volume: 404,694

Technical Sentiment Signal: Sell

Current Market Cap: $35.89M

Find detailed analytics on INMB stock on TipRanks’ Stock Analysis page.